

Norm Hovijitra

PARTNER

Technology
Transactions

nhovijitra@wsgr.com
650-849-3403



FOCUS AREAS

Biotech
Global Generics
Life Sciences
Technology Transactions

EXPERIENCE

Dr. Norm Hovijitra is a partner in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. He advises emerging and established companies in the life sciences industry on legal and business issues associated with the development, manufacture, and commercialization of their products and technologies, including matters relating to intellectual property strategy and patents.

Norm's practice focuses on the representation of clients in complex partnering and licensing arrangements, merger and acquisition transactions, and spin-outs. In addition, he advises clients on a range of related transactions such as license agreements with academic and nonprofit institutions; research and development services agreements; clinical trial agreements; and manufacture, supply, and distribution agreements.

Previously, Norm worked as a patent agent at the firm, focusing on patent preparation and prosecution, research related to intellectual property, and due diligence matters in the life sciences and clean technology industries.

Norm received his Ph.D. in chemical engineering at Stanford University, where he gained research experience in fermentation, molecular biology, and biochemistry. His graduate work focused on the production and characterization of membrane proteins and lipids.

Norm is practicing virtually in Hawaii, where he is licensed.

CREDENTIALS

Education

- J.D., Stanford Law School
- Ph.D., Chemical Engineering, Stanford University
Recipient, National Science Foundation Graduate Fellowship
- B.S., Chemical Engineering, Purdue University
With Honors of the Highest Distinction

Admissions

- State Bar of California
- State Bar of Hawaii
- U.S. Patent and Trademark Office

MATTERS

Select Transactions

- Link Therapeutics in its collaboration with Janssen
- Hexagon Bio in its joint venture with Corteva

- Kumquat in its collaboration with Bayer
- Baebies in its asset sale to LaCAR
- Candid in its licensing agreement with WuXi
- 10x in its settlement with Vizgen
- Kinnate in its acquisition by Xoma
- Amphastar in its asset purchase from Lilly
- Arcellx in its collaboration with Kite and expansion thereof
- IGM Biosciences in its collaboration with Sanofi
- Dren Bio in its collaborations with Pfizer and Novartis
- Crinetics in its spinout of Radionetics
- Alektor in its collaboration with GSK
- Rigel Pharmaceuticals in its collaboration with Lilly
- Denali Therapeutics in its collaborations with Biogen, Sanofi, and Takeda
- Vividion Therapeutics in its collaboration with Roche
- Vertex Pharmaceuticals in its collaborations with Obsidian Therapeutics and Arbor Biotechnologies
- Empirico in its collaboration and option with Ionis Pharmaceuticals
- Arrinex in its acquisition by Stryker
- Taiho Pharmaceutical in its option and collaboration with Arcus Biosciences
- Harpoon Therapeutics in its collaboration with AbbVie
- Maverick Therapeutics in its spinout from Harpoon Therapeutics and its collaboration and option to acquire with Takeda
- Eyemedics in its collaboration and option to acquire with Acucela
- ColonyConcepts in its asset sale to Sebel
- Array BioPharma in its collaboration with Asahi Kasei
- Nanostring in its collaboration with Merck
- Veniti in its option to acquire and distribution agreement with Boston Scientific
- Akarna Therapeutics in its acquisition by Allergan
- Jiangsu Hengrui in its license with Tesaro
- Oculeve in its acquisition by Allergan
- NantKwest in its initial public offering
- Google Life Sciences (now Verily Life Sciences) in its collaboration with Dexcom